2011

• April 14, 2011
  Neurotech’s NT-501 Implant Demonstrates Statistically Significant Photoreceptor Preservation in Patients with Retinal Degenerative Disease
• April 5, 2011
  Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy associated with Dry AMD as Reported in PNAS

2009

• May 28, 2009
  Results from Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
• March 26, 2009
  Positive Results from Neurotech's NT-501 Phase 2 Dry AMD (Geographic Atrophy) Study Demonstrate Proof of Concept

2008

• October 21, 2008
  Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
• September 3, 2008
  Neurotech Granted Fast Track Designations from the FDA for NT-501 in Two Indications—Retinitis Pigmentosa and Dry Age-Related Macular Degeneration
• January 25, 2008
  Neurotech Pharmaceuticals Announces Rhode Island Expansion Plan

2007

• November 6, 2007
  Neurotech Announces Completion of Enrollment of its Phase 2/3 Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
• August 8, 2007
  Neurotech Names Richard Small Chief Financial Officer
• April 17, 2007
  Neurotech Initiates two Phase 2/3 Clinical Trials of NT-501 for the Treatment of Retinitis Pigmentosa

2006

• November 16, 2006
  Neurotech Completes $35 Million Private Equity Financing
• March 15, 2006
  Neurotech Announces Publication of NT-501 Phase I Results in Proceedings of the National Academy of Sciences
• January 5, 2006
  Neurotech Initiates a Phase 2 Clinical Trial of NT-501 for the Treatment of Dry Age Related Macular Degeneration

2005

• October 13, 2005
  Neurotech Names Ted Danse as New President and CEO
• May 1, 2005
  Neurotech Announces Successful Completion of Phase 1
• March 14, 2005
  Neurotech Board Changes

2003

• November 24, 2003
  Neurotech Completes Euro 12 Million Private Financing
• October 8, 2003
  Neurotech Announces Initiation of a Phase 1 Clinical Trial to Evaluate the Safety of Ciliary Neurotrophic Factor Implant in the Eye
• March 24, 2003
  Neurotech Strengthens Its Position In Ophthalmology Through Collaboration With Inserm and the Quinze-Vingts Hospital, Paris

2002

• December 3, 2002
  Neurotech Reports in IOVS that Encapsulated Cell Based Delivery of CNTF Reduces Photoreceptor Degeneration in Animal Models of Retinitis Pigmentosa
• August 23, 2002
  Neurotech Refocuses on Ophthalmic Technologies
• April 26, 2002
  Neurotech Announces Senior Management Changes
• January 14, 2002
  Neurotech Signs License Agreement with Amgen